Halyard Health, Inc. (HYH) Upgraded at Stephens
A number of other equities research analysts also recently commented on the stock. TheStreet upgraded shares of Halyard Health from a c rating to a b- rating in a report on Thursday, April 6th. Zacks Investment Research upgraded shares of Halyard Health from a sell rating to a buy rating and set a $44.00 price target for the company in a report on Wednesday, May 3rd. Finally, BidaskClub upgraded shares of Halyard Health from a hold rating to a buy rating in a report on Wednesday, June 28th. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The company has an average rating of Buy and a consensus target price of $42.25.
Halyard Health (NYSE:HYH) traded up 0.28% during mid-day trading on Thursday, hitting $42.73. 122,164 shares of the stock traded hands. The firm’s 50-day moving average is $39.44 and its 200-day moving average is $38.58. Halyard Health has a 12-month low of $31.59 and a 12-month high of $42.81. The company has a market cap of $2.00 billion, a price-to-earnings ratio of 41.09 and a beta of 1.78.
Halyard Health (NYSE:HYH) last issued its quarterly earnings results on Wednesday, August 2nd. The medical instruments supplier reported $0.51 EPS for the quarter, topping analysts’ consensus estimates of $0.37 by $0.14. The business had revenue of $399.20 million during the quarter, compared to the consensus estimate of $399.16 million. Halyard Health had a net margin of 3.06% and a return on equity of 8.29%. The company’s quarterly revenue was down .2% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.45 earnings per share. Equities research analysts expect that Halyard Health will post $1.96 EPS for the current year.
Large investors have recently added to or reduced their stakes in the stock. BlackRock Inc. boosted its position in Halyard Health by 6,362.1% in the first quarter. BlackRock Inc. now owns 5,939,352 shares of the medical instruments supplier’s stock valued at $226,229,000 after buying an additional 5,847,442 shares during the period. Vanguard Group Inc. boosted its position in Halyard Health by 4.7% in the first quarter. Vanguard Group Inc. now owns 4,350,518 shares of the medical instruments supplier’s stock valued at $165,711,000 after buying an additional 196,367 shares during the period. Dimensional Fund Advisors LP boosted its position in Halyard Health by 18.8% in the first quarter. Dimensional Fund Advisors LP now owns 2,625,156 shares of the medical instruments supplier’s stock valued at $99,992,000 after buying an additional 415,105 shares during the period. State Street Corp boosted its position in Halyard Health by 1.8% in the first quarter. State Street Corp now owns 1,583,269 shares of the medical instruments supplier’s stock valued at $60,306,000 after buying an additional 28,718 shares during the period. Finally, Bank of New York Mellon Corp boosted its position in Halyard Health by 0.4% in the second quarter. Bank of New York Mellon Corp now owns 885,238 shares of the medical instruments supplier’s stock valued at $34,772,000 after buying an additional 3,596 shares during the period. Hedge funds and other institutional investors own 90.28% of the company’s stock.
Halyard Health Company Profile
Halyard Health, Inc is a medical technology company. The Company operates through two segments: Medical Devices and Surgical and Infection Prevention (S&IP). The Medical Devices segment provides a portfolio of product offerings focused on pain management, respiratory and digestive health. The S&IP segment provides healthcare supplies and solutions that target the prevention of healthcare-associated infections.
Receive News & Ratings for Halyard Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halyard Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.